确定接受地拉罗司治疗的骨髓增生异常综合征患者铁过载的参数。 - Suppr | 超能文献

Delineating parameters of iron overload in MDS patients treated with deferasirox.

作者信息

Leitch Heather A

出版信息

Leuk Res. 2010 Dec;34(12):1556-7. doi: 10.1016/j.leukres.2010.06.032. Epub 2010 Aug 17.

DOI:10.1016/j.leukres.2010.06.032

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Delineating parameters of iron overload in MDS patients treated with deferasirox.

Leuk Res. 2010 Dec;34(12):1556-7. doi: 10.1016/j.leukres.2010.06.032. Epub 2010 Aug 17.

2

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Leuk Res. 2010 Dec;34(12):1560-5. doi: 10.1016/j.leukres.2010.06.013. Epub 2010 Jul 8.

3

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

4

Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.

Transfusion. 2015 Jul;55(7):1613-20. doi: 10.1111/trf.13036. Epub 2015 Mar 11.

5

CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.

Oncol Res Treat. 2016;39(7-8):424-31. doi: 10.1159/000447035. Epub 2016 Jun 21.

6

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.

Eur J Haematol. 2012 Mar;88(3):260-8. doi: 10.1111/j.1600-0609.2011.01726.x. Epub 2011 Nov 24.

7

Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.

J Clin Pharm Ther. 2016 Feb;41(1):59-63. doi: 10.1111/jcpt.12348. Epub 2016 Jan 18.

8

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

9

Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.

Ann Hematol. 2009 Apr;88(4):301-10. doi: 10.1007/s00277-008-0588-3. Epub 2008 Aug 29.

10

Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.

Haematologica. 2010 Aug;95(8):1433-4. doi: 10.3324/haematol.2010.024992. Epub 2010 Apr 26.

引用本文的文献

1

Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Drugs. 2011 Jan 22;71(2):155-77. doi: 10.2165/11585280-000000000-00000.